The intraerythrocytic apicomplexan Babesia microti, the primary causative agent of human babesiosis, is a major public health concern in the United States and elsewhere. Apicomplexans utilize a multiprotein complex that includes a type I membrane protein called apical membrane antigen 1 (AMA1) to invade host cells. We have isolated the full-length B. microti AMA1 (BmAMA1) gene and determined its nucleotide sequence, as well as the amino acid sequence of the AMA1 protein. This protein contains an N-terminal signal sequence, an extracellular region, a transmembrane region, and a short conserved cytoplasmic tail. It shows the same domain organization as the AMA1 orthologs from piroplasm, coccidian, and haemosporidian apicomplexans but differs from all other currently known piroplasmida, including other Babesia and Theileria species, in lacking two conserved cysteines in highly variable domain III of the extracellular region. Minimal polymorphism was detected in BmAMA1 gene sequences of parasite isolates from six babesiosis patients from Nantucket. Immunofluorescence microscopy studies showed that BmAMA1 is localized on the cell surface and cytoplasm near the apical end of the parasite. Native BmAMA1 from parasite lysate and refolded recombinant BmAMA1 (rBmAMA1) expressed in Escherichia coli reacted with a mouse anti-BmAMA1 antibody using Western blotting. In vitro binding studies showed that both native BmAMA1 and rBmAMA1 bind to human red blood cells (RBCs). This binding is trypsin and chymotrypsin treatment sensitive but neuraminidase independent. Incubation of B. microti parasites in human RBCs with a mouse anti-BmAMA1 antibody inhibited parasite growth by 80% in a 24-h assay. Based on its antigenically conserved nature and potential role in RBC invasion, BmAMA1 should be evaluated as a vaccine candidate.
B
abesiosis is caused by tick-borne intraerythrocytic apicomplexan parasites of the genus Babesia that infect a wide variety of wild and domesticated animals (1) . Human cases have been reported throughout the world, including the United States, where it is endemic in the northeast and upper Midwest, and Europe, Asia, and Australia (2, 3) . Babesia usually are transmitted by Ixodes ticks but may be transmitted also by blood transfusion and transplacentally (4) (5) (6) . Babesia microti is the primary cause of babesiosis, with an increase in incidence in many areas of the United States of up to 4-fold to 20-fold in the last decade. To address this growing public health threat, the Centers for Disease Control and Prevention declared babesiosis a nationally notifiable disease in 2011 and consequently expanded surveillance from 18 states in 2011 to 33 states in 2013 (7) . B. microti infections in young and healthy adults generally cause a mild virus-like infection but may be asymptomatic. More-severe disease occurs primarily in neonates, the elderly, and those who are immunocompromised, with mortality rates as high as 20% (8, 9) .
One of the most salient features of Babesia and other apicomplexan parasites (e.g., Plasmodium and Toxoplasma) is a complex of specialized secretory organelles that include micronemes, rhoptries, and dense granules, which secrete molecules necessary for host cell invasion in a coordinated manner (10) . One such molecule is conserved apical membrane antigen 1 (AMA1), a type I membrane protein (11) . It is localized in micronemes and is subsequently expressed in a processed form circumferentially around merozoites (12) where it forms a multiprotein complex with other proteins in the moving junction (13) . The precise biological role of AMA1 is not known, but evidence based on its subcellular localization and data from genetic knockout and transspecies expression studies suggest that it facilitates invasion of red blood cells (RBCs) and further growth of intraerythrocytic Plasmodium parasites (14, 15) . Crystallization of complete and truncated forms of the extracellular region from Plasmodium vivax, P. falciparum, and Toxoplasma gondii (16) (17) (18) revealed that it contains three domains. Domains I and II are homologous to the PAN (plasminogen, apple, and nematode) domains, which facilitate protein-protein and protein-carbohydrate interactions among the members of a class of adhesion molecules (19) . AMA1 is a major malaria vaccine candidate, and its efficacy against asexual stage parasites is being evaluated in clinical studies (20) .
Despite its growing public health importance, very limited efforts have been made to understand the process of invasion of RBCs by B. microti parasites and the molecules that are associated with this process. Recently, X-ray crystallography data characterizing AMA1 from Babesia divergens and Neospora caninum was published (21) . Here, we report on the gene cloning, recombinant expression, genetic and biological characteristics, and natural polymorphism in the AMA1 of B. microti (BmAMA1).
MATERIALS AND METHODS

B. microti propagation in mice.
The Babesia microti (Franca) Reichenow Peabody strain (22) was obtained from the American Type Culture Collection (Manassas, VA). The Peabody strain was originally isolated in 1973 from a Nantucket woman and was adapted for growth in hamsters and mice. B. microti was injected into DBA/2NCr mice, and parasites were isolated when 10% to 20% of the RBCs were infected, as determined by the use of Giemsa-stained thin blood films. Mice were maintained at the Center for Biologics Evaluation and Research (CBER) animal care facility, and studies were conducted under an Animal Study Protocol approved by the CBER Animal Care and Use Committee.
B. microti from human patients. Human B. microti samples were obtained from six babesiosis residents of Nantucket in 2009. They were diagnosed with B. microti infection, based on typical symptoms and identification of Babesia on thin blood smears and/or amplification of B. microti DNA using PCR. B. microti-infected blood samples were stored at Ϫ80°C until use.
RNA, gDNA, and cDNA isolation. Total RNA was prepared by lysing B. microti-infected RBCs with TRIzol reagent (Life Technologies, Grand Island, NY), followed by chloroform extraction and precipitation performed with isopropyl alcohol and ethanol. Genomic DNA (gDNA) was prepared from B. microti-infected human blood and B. microti-infected mouse blood using a QIAamp DNA blood minikit (Qiagen, Valencia, CA). cDNA was prepared from RNA isolated from B. microti parasites grown in mice with the use of a SuperScript kit (Life Technologies) following the instructions provided by the company.
Gene cloning and nucleotide sequencing of BmAMA1. At the time when this research was conducted, the genome sequence of B. microti had not been published. To isolate the full-length BmAMA1 gene, the following approach was used to design the degenerate sequencing primers. Nucleotide sequences of AMA1 of B. bovis, B. gibsoni, B. bigemina, and B. divergens (GenBank accession no. AY486101, DQ368061, GQ257738, and EU486539, respectively) were aligned, and several sets of degenerate forward and reverse primers were synthesized and used to amplify partial sequences of the AMA1 gene from cDNA and gDNA. A set of degenerate primers (F1 [5= GGW AAR TGC CCA GTT 3=] and R1 [5= CTC SAR TGG WGA ACC 3=], corresponding to amino acid sequences GKCPV and GS PLE), gave a band with an amplicon size of 921 bp and was cloned into pCR2.1TOPO, sequenced, and aligned to the published Babesia AMA1 amino acid sequences. It was found to be ϳ39.7% similar to B. bovis AMA1, 34.8% similar to B. divergens AMA1, 37.4% similar to B. gibsoni AMA1, and ϳ29% similar to P. falciparum AMA1. Several forward and reverse gene-specific primers were synthesized to clone the full-length cDNA. Briefly, rapid amplification of cDNA ends (RACE)-ready cDNA was obtained from total parasite RNA following the instructions provided in a GeneRacer kit (Life Technologies). RACE reactions were performed with the 5= GeneRacer primers and 3= gene-specific primers SK687 and SK686 (parent and nested oligonucleotides). 3= RACE was performed with 5= gene-specific primers SK670 and SK671 and 3= GeneRacer primers (parent and nested oligonucleotides) (Table 1) . Finally, nucleotide sequences obtained from 5= and 3= RACE products were overlaid to obtain the full transcript sequence and then the full-length gene was amplified using cDNA as a template.
Recombinant expression, purification, and refolding of BmAMA1. The gene fragment encoding the BmAMA1 extracellular region corresponding to amino acids A 41 to G 529 was PCR amplified by using the primer sets listed in Table 1 . The amplified gene fragment was cloned into pCR2.1TOPO vector (Invitrogen), the nucleotide sequence was determined, and the plasmid was maintained in TOP10 Escherichia coli competent cells. To construct the recombinant expression plasmid, the extracellular region of the gene was cloned into pET101/D-TOPO (Champion pET101 Directional TOPO expression kit; Invitrogen), which has a 6ϫHis tag to facilitate purification, and then transformed into BL21 Star (DE3) One Shot chemically competent E. coli cells. For recombinant expression, 500 ml LB medium was inoculated with 5 ml overnight culture, and the culture was grown at 37°C to an A 600 of 0.5 and then induced with 0.5 mM GeneRacer 5= primer  5=-CGACTGGAGCACGAGGACACTGA-3=  SK687R  5=-GGCGGTGACGTTTGCAGGAG-3=   5= RACE (nested)  GeneRacer 5= nested primer  5=GGACACTGACATGGACTGAAGGAGTA-3=  SK686R  5=-CCCAAAAACTGGGCATTTTCC-3=   3= RACE  SK670F  5=-GGAAAATGCCCAGTT-3=  GeneRacer 3= primer  5=-GCTGTCAACGATACGCTACGTAACG-3= 3= RACE (nested) SK671F 5=-TATTGTGATAATGATGGA-3= GeneRacer 3= nested primer 5=-CGCTACGTAACGGCATGACAGTG-3=
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IPTG (isopropyl-␤-D-thiogalactopyranoside). After 4 h, cells were pelleted and stored at Ϫ80°C until use. The procedure for on-column refolding and purification was performed essentially as described by Saini et al. (23) . Briefly, the cell pellet was resuspended in sonication buffer 20 mM Tris-HCl [pH 8.0], 300 mM NaC1, 0.5 mM dithiothreitol [DTT], 1ϫ protease inhibitors-EDTA free [Roche] and lysed on ice with a sonicator. The inclusion bodies were resuspended in solubilization buffer (20 mM Tris-HCl [pH 8.0], 300 mM NaCl, 6 M GdnHCl) and incubated at room temperature (RT) for 2 h with shaking, followed by centrifugation at 15,000 ϫ g for 30 min. The supernatant was loaded onto a preequilibrated Ni 2ϩ -nitrilotriacetic acid (NTA) agarose column and incubated for 3 h at room temperature. The column was washed with 3 bed volumes of solubilization buffer and then washed with decreasing concentrations (6 to 0 M) of GdnHCl in refolding buffer (20 mM Tris-HCl [pH 8.0], 300 mM NaC1, 10% glycerol, 20 mM imidazole, 0.5 mM oxidized glutathione, 5 mM reduced glutathione). The bound protein was eluted with refolding buffer containing 200 mM imidazole in fractions of 1 ml, the fractions were checked by SDSpolyacrylamide gel electrophoresis (PAGE), and the peak fractions were pooled and dialyzed against phosphate-buffered saline (PBS) and again separated by gel-filtration chromatography using a Superdex 75 10/300 column (GE Healthcare, Piscataway, NJ). Fractions containing recombinant BmAMA1 were pooled, quantitated, divided into aliquots, and stored in Ϫ80°C. NH 2 -terminal amino acid sequencing was performed by the Edman degradation method to confirm the identity of the purified recombinant BmAMA1 protein (which has been named "rBmAMA1").
BmAMA1 DNA plasmid vaccine. The VR1020 DNA vaccine plasmid has a strong cytomegalovirus promoter and a tissue plasminogen activator (TPA) signal sequence, which promotes the secretion of the cloned gene. The gene fragment encoding a BmAMA1 extracellular region (G 148 to E 454 ) was PCR amplified using primer set SK682 and SK683 (see Table  1 ) and cloned into the BamHI restriction site of the VR1020 mammalian expression plasmid (24) . The recombinant plasmid containing the BmAMA1 extracellular-region gene was identified by restriction mapping, and the nucleotide sequence was determined. The DNA plasmid for mouse immunizations was purified by the use of a Mega Plasmid preparation kit (Qiagen).
Nucleotide sequencing of BmAMA1 from clinical and field isolates. Blood samples were obtained from six individuals infected with B. microti from Nantucket, MA. B. microti gDNA was extracted, and the BmAMA1 extracellular-region gene fragments (nucleotides 442 to 1362, corresponding to amino acids G 148 to E 454 ) from each of the human six samples and from the B. microti Peabody-strain parasites grown in mice were PCR amplified by the use of primers SK670F and SK675R ( Table 1 ). The BmAMA1 extracellular-region gene fragments were then cloned into TOPO vector (Invitrogen) and their nucleotide sequences determined.
Sequence analysis. Iterative sequence searches were performed using the PSI-BLAST programs against the NCBI nonredundant (NR) protein database (25) . Multiple-sequence alignments were built using Kalign2 or Muscle, followed by manual adjustments based on profile-profile comparisons, secondary structures, and structural alignments. Similaritybased clustering for both classification and culling of nearly identical sequences was performed using the BLASTCLUST program (ftp://ftp .ncbi.nih.gov/blast/documents/blastclust.html). Structural visualization and manipulations were performed using the PyMol program (http: //www.pymol.org). Signal peptide and transmembrane helices were predicted using SignalP 3.0 and TMHMM v1.0 programs (CBSA, Technical University of Denmark, Denmark), respectively. From multiple alignments of each set of AMA1 sequences, the Shannon entropy (H) for each position was calculated using a custom script with the following equation:
where P i is the fraction of residues of amino acid type i and M is the number of amino acid types.
Generation of anti-BmAMA1 antibody. Female Swiss outbred mice (6 to 8 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME) and were housed, fed, and used in the experiments in accordance with the guidelines set forth in the National Institutes of Health manual Guide for the Care and Use of Laboratory Animals. Mice (4 per group) were immunized with BmAMA1 extracellular-region DNA plasmid by three intradermal injections using 50 g of DNA plasmid delivered at the base of the tail at 4-week intervals. Control mice were immunized with a recombinant plasmid containing a gene insertion encoding B. microti cysteine protease protein or mice that did not receive any immunization. Nonheparinized blood was collected from the tail vein of all the experimental and control mice at the time of each immunization and 10 days after the last booster. Serum samples were collected and stored at Ϫ20°C until use.
ECL-Western blot analysis. Enhanced chemiluminescence (ECL)-Western blot analysis was performed as described earlier (26) . Briefly, purified rBmAMA1 was subjected to NuPAGE 4% to 12% Bis-Tris SDS-PAGE (Invitrogen) and transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were blocked in 2% I-Block (Life Technologies) and incubated with a mouse anti-BmAMA1 antibody (1:2,000 dilution) for 1 h. Following washings, the membrane was incubated with ECL-goat alkaline phosphatase (AP)-conjugated anti-mouse IgG (1:5,000 dilution) for 1 h. Following additional washings, the membrane was reacted with ECL substrate solution (Western-Star immunodetection system; Life Technologies, Grand Island, NY), exposed to Kodak X-Omat autoradiography (XAR) film (VWR Scientific, Radnor, PA), and developed using a Kodak developer (X-Omat 1000A).
Immunofluorescence antibody assay (IFA). B. microti-infected mouse RBCs were washed, and the RBC membrane was stained by the use of a PKH26 red fluorescent cell membrane labeling kit (Sigma-Aldrich, MO, USA) according to the manufacturer's protocol, fixed in 3% paraformaldehyde-10 mM PIPES [piperazine-N,N=-bis (2-ethanesulfonic acid)] buffer (pH 6.4)-PBS for 30 min at RT, smeared on poly-L-lysinecoated 22-mm 2 coverslips, permeabilized with 0.25% Triton X-100 -PBS, washed three times in PBS, and blocked in 5% bovine serum albumin (BSA)-PBS for 30 min (27) . Coverslips were incubated in immune mouse serum diluted 1:20 in BSA-PBS for 1 h, washed three times in PBS, and incubated in goat anti-mouse Alexa Fluor 488 (Invitrogen) for 1 h. Coverslips were washed three times with PBS, briefly swirled in distilled water, and mounted in antifade reagent Vectashield containing DAPI (6-diamidino-2-phenylindole) over a glass slide and sealed with nail polish. The samples were imaged with a Leica TCS_SP8 DMI6000 confocal microscope system (Leica Microsystems, Mannheim, Germany) with a 100ϫ 1.4-numerical-objective (NA) oil objective lens. Images were acquired at a resolution of 1,024 by 1,024 pixels and stored in lif format for further analysis. Huygens (Scientific Volume Imaging, Hilversum, Netherlands) and Imaris (Bitplane AG, Zurich, Switzerland) software was used for deconvolution and image analysis (28) .
Enzymatic treatment and RBC ghost preparation. Whole blood (O positive [O ϩ ]) from random volunteers was obtained from the NIH Blood Bank. After leukoreduction, RBCs were washed three times with PBS and treated with 0.01 U/ml neuraminidase (Sigma), 1 mg/ml trypsin (Sigma), and 1 mg/ml chymotrypsin (Sigma) for 1 h. After three washes, trypsin-treated RBCs were further subjected to treatment with 0.5 mg/ml soybean trypsin inhibitor for 30 min at RT (29) . RBCs were washed three times with PBS, and RBC membranes (white ghosts) were subjected to lysing with cold 5 mM NaP (pH 8.0) (30, 31) for 30 min on ice, centrifuged at 15,000 ϫ g, and washed three times to obtain white ghosts. These white ghosts were used for binding assays.
RBC-binding assay. The ability of BmAMA1 to bind to human red blood cells (RBCs) was determined with an RBC-binding assay. Both native (parasite) and recombinant (E. coli) expressed BmAMA1 proteins were used in the assay.
RBC binding using native BmAMA1. B. microti parasites for use in the RBC-binding assay were prepared from infected RBCs collected from DBA/2 mice when the level of parasitemia was 25% to 30%. The RBCs were washed three times in PBS, subjected to lysis using a protocol described by Martin et al. (32) , and then washed three times with cold PBS. The binding assay was performed as described by Yokoyama et al. (33) . Briefly, pellets containing approximately 10 9 parasites were suspended in 1 ml of a lysis buffer (50 mM Tris-HCl [pH 7.5], 0.1% Triton X-100, 150 mM NaCl, 20% glycerol, 0.5 mM EDTA, 1 mM phenylmethylsulfonyl fluoride [PMSF], 1 mM dithiothreitol [DTT] , and 1ϫ protease inhibitor [Roche]), incubated on ice for 30 min, and then centrifuged at 18,000 ϫ g for 30 min at 4°C. These clarified lysates were dialyzed overnight against dialysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 20% glycerol, 0.5 mM EDTA, 1 mM PMSF, 1 mM DTT) with three changes of buffer. The dialysates were again centrifuged at 18,000 ϫ g for 30 min at 4°C, and the supernatants were stored at Ϫ80°C until use. The cell extracts were equally divided, and the aliquots were incubated with 20 l of human RBC ghosts for 6 h at 4°C. RBC ghosts were precipitated by centrifugation at 10,000 ϫ g for 10 min at 4°C, washed in 1 ml of a dialysis buffer three times, suspended in 50 l of 2ϫ SDS sample buffer, and heated at 100°C for 10 min. After centrifugation at 13,000 ϫ g for 5 min at room temperature, the supernatants were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) with a 4% to 12% polyacrylamide gel. Western blot analysis was carried out with the anti-AMA1 antibody.
RBC binding using rBmAMA1. An RBC-binding assay using rBmAMA1 was performed using a modification of a procedure described earlier (34) . RBC ghosts were incubated with 25 g of recombinant BmAMA1 for 2 h at RT and washed extensively in PBS to remove the unbound protein. The pellet was resuspended in 4ϫ SDS sample loading buffer, boiled for 5 min at 100°C, and subjected to SDS-PAGE and ECLWestern blot analysis to determine the binding affinity of untreated and enzymatically treated RBC membranes with the native or recombinant BmAMA1. To obtain a semiquantitative estimation of bound native BmAMA1 and rBmAMA1 levels, the intensities of individual bands were measured as pixel units in a defined area by using the ImageJ program (26) and expressed as integrated optical density (IOD) values. The relative percentages of binding of native BmAMA1 or rBmAMA1 to RBC were determined as follows: IOD of enzymatically treated RBC/IOD of untreated RBC ϫ 100.
To demonstrate successful removal of sialic acids and to confirm effective enzymatic digestion, RBCs were treated with neuraminidase and RBC ghosts were prepared as described earlier. An independent assay was conducted where untreated and neuraminidase-treated RBC ghosts were stained using a Thermo Scientific Pierce glycoprotein staining kit and the periodic acid-Schiff (PAS) method (see the supplemental material). For RBC-binding assay, untreated and neuraminidase-treated membranes were incubated with parasite extracts and subjected to SDS-PAGE, and Western blot analysis was carried out with anti-AMA1 antibody (see the supplemental material).
Growth inhibition assay. This assay was performed using a procedure described earlier by Sun et al. (35) with slight modification. B. microtiinfected RBCs from DBA/2 mice were collected when parasitemia reached 25% to 30%, washed three times in PBS, and subjected to lysis using a protocol described by Martin et al. (32) . Isolated B. microti parasites (merozoite and intracellular forms) were washed and resuspended in RPMI 1640 -10% fetal calf serum (FCS). The number of B. microti parasites per microliter of solution was determined by the use of Count Bright Absolute counting beads according to the manufacturer's protocol (Invitrogen). The total RBC count per microliter of the suspension was determined by using a hemocytometer. Parasites suspended in RPMI 1640 were incubated with pooled heat-inactivated mouse anti-BmAMA1 sera or preimmune sera at a final dilution of 1:15 for 1 h at room temperature. The parasites were then added to normal human RBCs (2% hematocrit) at a level equivalent to a final parasitemia level of 1% in 96-well tissue culture plates in triplicate. After 8 and 24 h of incubation at 37°C, RBCs were collected, centrifuged at 300 ϫ g for 5 min, and washed three times with PBS to remove the unbound parasites. Giemsastained thin blood films from each well were prepared, and the percentage of B. microti-infected RBCs was determined by counting approximately 1,000 cells for each sample using oil immersion light microscopy. The experiment was repeated three times. The percentage of inhibition of merozoite invasion was determined using the following formula: [1 Ϫ percent parasitemia with test sera/percent control (preimmune sera) parasitemia] ϫ 100%.
Statistical methods. A comparison of the relative percentages of inhibition of growth of B. microti parasites in human RBCs was made using anti-BmAMA1 sera and preimmune sera after 8 h and 24 h cultivation. The Mann-Whitney nonparametric test was used to evaluate the differences between the two test sera in the relative percentages of growth. All data were evaluated using a two-sided hypothesis test. A P value of Ͻ0.05 indicated statistical significance. All statistical analyses were implemented by the use of "R" statistical software.
Nucleotide sequence accession number. The full-length BmAMA1 cDNA sequence described in this paper has been deposited in the GenBank database under accession number JX488467 (GI number 490386734).
RESULTS
BmAMA1 gene cloning and nucleotide sequence. Sets of forward and reverse degenerate primers were initially designed from consensus sequences of aligned amino acids of AMA1 of four Babesia species (B. bovis, B. gibsoni, B. bigemina, and B. divergens) that corresponded to conserved GKCPV and GSPLE sequences. A PCR product of 921 bp encoding 307 amino acids (aa) was obtained from gDNA of B. microti that was cloned into TOPO 2.1 vector, and the nucleotide sequence was determined. To obtain fulllength BmAMA1, gene-specific forward and reverse primer sets were synthesized from this sequence and primers from a GeneRacer kit (Invitrogen) were used to derive the N-and C-terminal sequences from a B. microti cDNA. This approach allowed assembly of the complete BmAMA1 cDNA that corresponded to approximately 2,100 bp, which was subcloned into the TOPO TA vector, and the nucleotide sequence was determined. The deduced BmAMA1 sequence was aligned with the four published Babesia AMA1 sequences mentioned above and was used to establish the start of translation and the translated open reading frame (ORF). The analysis of the nucleotide sequence of BmAMA1 cDNA revealed an ORF of 1,845 bp preceded by a 172-bp 5= noncoding region preceding the first methionine codon. A 3= untranslated region of 102 bp contained a 25-bp-long poly(A) tail. A small intron of 23 bp located after the position 134 nucleotides from the initial ATG codon was identified in the gDNA sequence.
We next sought to determine the copy number of BmAMA1 in the parasite genome. To accomplish this, B. microti gDNA was digested with restriction enzymes and then subjected to Southern blot analysis and hybridized under highly stringent conditions with the BmAMA1 extracellular-region probe of 921 bp. Analysis of the pattern of hybridization revealed that the gene encoding BmAMA1 was present as a single-copy gene (data not shown). This result is further corroborated by the recently published B. microti genome sequence (36) , which suggests the presence of a single copy of the BmAMA1 gene on chromosome 3. (Fig. 1A) . The sequence of BmAMA1 derived from the B. microti genome sequence has been erroneously predicted (GenBank gi no. 399217547; BBM_III01160). As a consequence, the N-terminalmost parts, including the signal peptide, have been fused to the adjacent gene. This work presents for the first time a corrected version of the BmAMA1 sequence. Examination of the multiple alignments of the sequences of AMA1 reveals that the basic pattern of three domains in the extracellular region (domains I to III) is preserved across all apicomplexans (Fig. 1B) . The first two of these are PAN domains, which are observed in bacterial and eukaryotic extracellular proteins. Within the two PAN domains, there are 10 cysteines, which are almost universally conserved across all species. The C-terminal domain (III) has a core sheet formed by 4 strands which contains 4 conserved cysteines largely preserved across all species. However, B. microti is unique (differing even from other piroplasmida) in that it lacks two of the cysteines forming a disulfide bond in the C-terminal domain. Thus, the extracellular region of B. microti contains 6 disulfide bridges in contrast to the 7 contained in other piroplasmida. Domain III of most coccidian and haemosporidian versions contains an additional cysteine dyad, suggesting that these AMA1 proteins form a total of 8 disulfide bonds.
BLAST searches performed with BmAMA1 helped identify its orthologs from other piroplasmida (Theileria and other Babesia species) and haemosporidian (Plasmodium species) and coccidian (Toxoplasma, Eimeria, and Neospora) apicomplexans. However, no AMA1 orthologs were detected in the more basal apicomplexan lineages such as Cryptosporidium. A phylogenetic tree constructed with the complete sequences of AMA1 from the organisms listed above showed that the coccidian versions form the most basal clade, with the two vertebrate blood-infecting clades (piroplasmida and haemosporidia) grouping together (Fig. 2) . Interestingly, while all coccidians have at least 3 paralogs of AMA1 in their genome, both the blood-infecting clades have only a single ortholog. Within the piroplasma, the version from B. microti groups outside the clade unites other Babesia species (Babesia bigemina, Babesia divergens, Babesia gibsoni, and Babesia ovata) and the Theileria group (Theileria parva, Theileria annulata, Theileria orientalis, and Theileria equi/Babesia equi). These findings are consistent with previous phylogenetic analyses which suggest that B. microti is a distinct lineage of piroplasmida outside the classical Theileria and Babesia genera (37) . Minimal polymorphism in the BmAMA1 gene in B. microti human isolates and comparison to other apicomplexans. We wanted to know the extent of natural polymorphism in BmAMA1. To accomplish this, we isolated the gene fragments for the extracellular region (G 148 to E 454 ) of BmAMA1 from six B. microtiinfected individuals from Nantucket in 2009, determined their nucleotide sequences, and then compared them to the laboratoryadapted B. microti Peabody strain that was isolated in Nantucket in 1973 for determination of nucleotide and amino acid polymorphisms. There was 99.9% homology at the amino acid level and 99.98% homology at the nucleotide level among these six BmAMA1 sequences. The extracellular-region BmAMA1 sequences from the three Nantucket clinical isolates were identical to that of the laboratory-adapted B. Despite the lack of variability in our current sample set, we sought to better understand the general tendencies of variability in piroplasma AMA1 with respect to other apicomplexans which possess orthologs of this protein. Given the rapid evolution of the AMA1 genes across apicomplexans with multiple amino acid substitutions at aligned sites, they are not amenable to a conventional positive-selection analysis using the ratios of nonsynonymous to synonymous evolutionary changes (Dn/Ds ratios). Hence, we used a parallel approach based on Shannon entropy plots to study the per-site amino acid variation in the fungal TET/JBP proteins (38) . In this analysis, we compared the levels of variability within the piroplasma, which include B. microti as the outgroup corresponding to the clade uniting the Theileria species and other Babesia species. This allowed us to analyze local regions of high variability within piroplasma (i.e., regions with high per-site entropy). In general, we observed that, in the extracellular region, specific domain III showed the greatest variability throughout most of its length, barring the conserved cysteines. In both domain I and domain II (the PAN domains), the maximum variability was concentrated in certain exposed loops, which are regions that are likely to be exposed to immune attack. We next compared these to the similar variability plots in Plasmodium and across all apicomplexa with AMA1. Regions of high variability in piroplasma (at least in the two PAN domains) showed some correlation to the variability across the Apicomplexa (Pearson correlation ϭ 0.55 to 0.67). Thus, it appears that across the Apicomplexa, some of the equivalent exposed regions are attacked as a result of the host immune response and thereby prone to rapid evolution. However, the lower correlation between the genus Plasmodium and piroplasma (Pearson correlation ϭ 0.25) suggests that there might also be lineage-specific pressures that shape the variability in the extracellular region.
Antigenic characterization of native BmAMA1 and rBmAMA1. Native BmAMA1 was identified in the B. microti parasite lysate based on reactivity with mouse anti-BmAMA1 antibody generated by immunization with BmAMA1 DNA plasmid vaccine. Native protein migrated as a band at ϳ78 kDa (p78), and a possible proteolytic cleaved fragment of 37 kDa (p37) was observed in ECL-Western blot analysis (Fig. 3A) . The predicted molecular mass of BmAMA1 is 69 kDa (p69). Thus, while p78 may represent the full-length AMA1 expressed by B. microti, the nature of p37 remains unclear.
The extracellular BmAMA1 encoding amino acids A 41 to G 529 was cloned in pET101/D-TOPO with a C-terminal His tag and viral V5 epitope and expressed in E. coli. The recombinant protein was present in the inclusion bodies, which were solubilized in 6 M GdnHCl, refolded on a Ni 2ϩ -NTA agarose column, eluted with 200 mM imidazole, and again purified on a Superdex 75 10/300 size exclusion column. The identity of rBmAMA1 was determined by electrophoretic migration in PAGE, ECL-Western blot analysis, and NH 2 -terminal amino acid sequencing. Though the predicted molecular mass of the His 6 -tagged extracellular region is 60 kDa (p60), under the nonreducing conditions, it migrated at a molecular mass of 67 kDa (p67) in 4% to 12% SDS-PAGE (Fig. 3B , lane 1) and exhibited slower migration under reduced conditions (lane 2). NH 2 -terminal amino acid sequencing confirmed the first 12 amino acids of p67 BmAMA1 (data not shown). A second band at approximately 54 kDa also was observed (Fig. 3B ) which corresponded to a proteolytic fragment of full-length BmAMA1 as confirmed by NH 2 -terminal amino acid sequencing (cleaved at position S 205 ). ECL-Western blot analysis revealed that both rBmAMA1 protein bands were reactive with the mouse antiBmAMA1 antibody (Fig. 3C) .
Localization of BmAMA1 in intraerythrocytic B. microti merozoites by immunofluorescence. The localization of BmAMA1 in intraerythrocytic B. microti parasites was determined by immunofluorescence analysis using a mouse anti-BmAMA1 antibody. Following staining of RBC membrane with PKH26 and incubation with the anti-BmAMA1 antibody, intraerythrocytic parasites were counterstained with an anti-mouse IgG conjugated to Alexa Fluor 488 and the nucleus was stained with DAPI. The presence of the DAPI-stained parasite nucleus is shown in blue, while a specific reactivity of anti-BmAMA1 antibody (shown in green) was detected on B. microti merozoites (Fig. 4) . We observed that about 26% of B. microti-infected RBCs had a fluorescence pattern that was consistent with reactivity with anti-BmAMA1 antibody. BmAMA1 appeared to be localized peripherally, with a concentration near the apical end (based on the apparent shape of the parasite) along with the regions of condensed peripheral cytoplasmic localization (Fig. 4 , merged color image). Parasites labeled with preimmune serum lacked any specific fluorescent signal.
BmAMA1 binds to human RBCs, and the RBC receptor for BmAMA1 is sensitive to treatment with trypsin and chymotrypsin. We wanted to determine whether BmAMA1 binds to human RBCs and whether it plays a role in B. microti invasion of RBCs. To accomplish this, we used a standardized RBC-binding assay where native BmAMA1 (parasite lysate) and rBmAMA1 were incubated with untreated and enzymatically treated RBC membranes. We also used anti-BmAMA1 antibody to detect the bound AMA1 in a semiquantitative ECL-Western blot. The band density representing the rBmAMA1 bound to RBCs in ECL-Western blot analysis was measured as the integrated optical density (IOD). RBCs were treated with neuraminidase, trypsin, and chymotrypsin, which selectively cleave different moieties of membrane proteins.
PAS staining of neuraminidase-treated ghost RBCs did not show staining of glycoproteins, whereas the glycoproteins of untreated ghost RBCs were effectively stained with PAS (see Fig. S1 in the supplemental material). These results suggested that the neuraminidase treatment did effectively remove the sialic acid residues on ghost RBCs.
The RBC-binding assay performed with parasite lysate revealed that native BmAMA1 binds to untreated and neuraminidase-treated human RBC ghost membranes (Fig. 5A, lanes 1 and  2) but not following trypsin or chymotrypsin treatment (lanes 4 and 5). RBC membranes treated only with trypsin inhibitor had no effect on the binding (lane 3). No bands were observed when untreated membranes were incubated with lysate from noninfected mouse RBCs (Fig. 5A, lane 6) . IOD measurements of the protein bands showed that the highest BmAMA1 binding occurred in untreated RBCs (IOD, 214.6 K [where K is 1,000]; 100% binding), neuraminidase-treated RBCs (IOD, 180.8 K; 15.8% reduction), and trypsin inhibitor-treated RBCs (208.6 K; 2.8% reduction), suggesting that this binding is neuraminidase independent (Fig. 5A) . Because neuraminidase primarily removes sialic acid residues, these data suggest that BmAMA1 binding is not mediated through ␣2-3-linked sialic acid residue-containing proteins on the surface of RBCs. On the other hand, RBC treatment with trypsin (IOD, 25.7 K; 88.1% reduction) and chymotrypsin (IOD, 5.0 K; 97.7% reduction) almost completely abolished the binding (Fig. 5A) , suggesting the protein nature of the receptor moiety on RBCs. While trypsin treatment of RBC membranes removes glycophorin A and glycophorin C (39), chymotrypsin cleaves integral membrane protein band 3 of RBCs (40) .
We have also observed a similar binding trend of rBmAMA1 with human RBCs. The highest rBmAMA1 binding was detected in untreated RBCs (IOD, 269.3 K; 100% binding) and in neuraminidase-treated RBCs (IOD, 261.5 K; 2.9% reduction), indicating that this binding is neuraminidase independent (Fig. 5B ). RBC treatment with trypsin (IOD, 10.6 K; 96.1% reduction) and chymotrypsin (IOD, 40 K; 85.2% reduction) abolished the binding (Fig. 5B) , Thus, the ligand binding of BmAMA1 to RBC membranes can be attributed to the presence of a receptor sensitive to trypsin and chymotrypsin. No binding of RBC membrane was observed with the purified, E. coli-expressed Plasmodium falciparum circumsporozoite protein that served as a negative control (Fig. 5C) .
Inhibition of in vitro B. microti growth in human RBCs by anti-BmAMA1 antibody. Among apicomplexans, AMA1 proteins are secreted from micronemes and are thought to be involved in host cell invasion (41) . Antibodies raised against AMA1 have been shown to effectively block the invasion of P. falciparum (42, 43) , T. gondii (44) , B. bovis (45, 46) , and B. divergens (47) parasites into host cells. Accordingly, we determined the inhibitory effect of a mouse anti-BmAMA1 polyclonal antibody directed against rBmAMA1 domains I and II on the growth of B. microti parasites in human RBCs after 8 h and 24 h of cultivation in three independent experiments. Compared to the medium control (PBS) and preimmune group results, anti-BmAMA1 sera exhibited very strong growth inhibitory activity. At 8 h postcultivation, parasitemia levels were 4.8% (medium control), 5.2% (unimmunized group), and 1.2% (anti-BmAMA1). A similar level of inhibitory effect was also evident after 24 h of cultivation, with parasitemia levels of 5.4% (medium control), 5.2% (unimmunized group) and 1.0% (anti-BmAMA1) (Fig. 6) . Overall, antiBmAMA1 antibody had highly significant inhibitory effects that corresponded to 82% and 80% (P Ͻ 0.005) growth inhibition after 8 h and 24 h of cultivation, respectively. However, as the parasite growth was unchanged between 8 and 24 h of cultivation, it is possible that multiplication became stationary after 8 h and that the anti-BmAMA1 antibody mediated the protective effect through invasion inhibition rather killing of intraerythrocytic parasites.
DISCUSSION
AMA1 is a low-abundance type I integral membrane protein, and evidence suggests that this molecule serves an important function during invasion in apicomplexan parasites (14, 45, 47, 48) . In this paper, we report on the gene cloning, recombinant expression, and genetic and biological characterization of BmAMA1, a B. microti homologue of B. divergens, B. bovis, Plasmodium, and Toxoplasma AMA1. Our studies have confirmed the presence of AMA1 in B. microti parasite (Fig. 3A and 4) . While a slower migration pattern observed under the reduced conditions indicated the recreation of conformation-dependent bonds ( Fig. 3B and C) , additional antigenic characterization and research may be needed to produce rBmAMA1 that is immunologically closer to the native protein.
The general antigenic structure of BmAMA1 resembles that of AMA1 of other apicomplexan parasites. It has an N-terminal signal sequence followed by an extracellular region, a transmembrane region, and a short cytoplasmic domain. The AMA1 sequence derived from gDNA of B. microti has a small 23-nucleotide intron compared to the sequence derived from cDNA. The presence of short introns is a common occurrence in B. microti; genome sequencing has revealed that about 70% of all B. microti genes contain introns of 20 to 25 bp in length (36) . We found that the BmAMA1 gene sequence was highly conserved among B. microti parasites from Nantucket Island, MA. Only 3 amino-acidlevel mutations were detected in the 307-amino-acid extracellular region from six parasite isolates that we sequenced. AMA1 is highly polymorphic in P. falciparum and P. vivax. Domain I is the most variable portion of the protein (49) . Allelic polymorphisms in AMA1 allow antigenic escape in antibody-dependent inhibition of invasion in P. falciparum cultures (42, 43) . The regions of variability of AMA1 generally correlate with those found across all apicomplexans. Thus, we cannot rule out the possibility that the lack of antigenic polymorphism in BmAMA1 from the isolates that we have analyzed might be due to the small sample size from a small geographical locus. Nonetheless, antigenic polymorphism is not unusual in Babesia spp. and has been observed in surfacecoating protein Bd37 between B. divergens isolates (50), in variable-merozoite-surface antigen (VMSA) in B. bovis (51, 52) , and in the products of the BMN1 family of genes in B. microti (53) . It is possible that the lack of polymorphism in BmAMA1 can be attributed to the high degree of adaptation of B. microti to its natural reservoir host and the lack of genetic recombination following infection in humans because they are dead-end hosts and thus fail to transmit infection to the tick vector.
The general conservation in the PAN domains (domain I and domain II) of the AMA1 proteins suggests that they might bind comparable glycoprotein receptors across apicomplexan species (16, 54) . However, domain III, which is closer to the parasite membrane, is far more variable between different apicomplexan lineages and also between B. microti and other piroplasmas. This suggests that it might be under fewer selective constraints or that this variability relates in some way to immune evasion. The cytoplasmic tail of BmAMA1 is a 58-amino-acid-long protein (comparable to other AMA1 proteins) whose phosphorylation plays a very important role in Plasmodium and Toxoplasma during erythrocyte invasion (55, 56) . The presence of conserved sequence motifs in the cytoplasmic tail of B. microti comparable to those in other apicomplexans suggests that it mediates similar extracellular interactions. Rhoptry neck protein 2 (RON2), RON4, RON5, and RON8 form a complex with AMA1 during the invasion process (48, 57) , and rhomboid 4 (ROM4) cleaves AMA1 in the C-terminal transmembrane domain, releasing the cytoplasmic tail of AMA1, which triggers the replication signal in Toxoplasma (58) . Immunofluorescence studies have indicated that BmAMA1 has a peripheral localization on the B. microti merozoite, with a concentration near the apical end with the regions of condensed peripheral cytoplasmic localization (Fig. 5) . These results are consistent with the reported localization of AMA1 at the apical ends and on the merozoite surface in B. divergens and P. falciparum.
The invasion of RBCs by Plasmodium parasites is a multistep process involving an interaction between receptors on the RBC surface and parasite ligands secreted from apical organelles that utilize several sialic acid-dependent and -independent pathways (59). In P. falciparum, interaction between AMA1 and RON2 is essential for junction formation with the RBCs (48, 60) ; however, the precise role of AMA1 in invasion remains a matter of debate (61) . Whether a similar type of engagement between AMA1 and RON2 is essential in B. microti invasion of RBCs has not been studied. These receptor-ligand interactions are characterized by their enzyme sensitivity to neuraminidase, trypsin, and chymotrypsin. Our results show that the parasite-produced native BmAMA1 and rBmAMA1 extracellular regions both bind to receptors on RBC membranes that are trypsin and chymotrypsin sensitive and neuraminidase resistant (Fig. 5) . Similar receptor binding profiles have been demonstrated with AMA1 in B. divergens (47) and in P. yoelli (62) . Although the specific receptor on the RBC surface is not known, the neuraminidase-resistant nature of BmAMA1-RBC binding (Fig. 5) indicates that the interaction is not mediated by sialic acid residues on the glycoproteins of RBCs. In B. bigemina, neuraminidase or trypsin treatment of bovine RBCs significantly reduced their susceptibility to invasion but chymotrypsin treatment had little effect (63) , indicating that a diverse array of RBC receptors may be involved in the invasion process which could be Babesia species dependent. Furthermore, the fact that mouse anti-BmAMA1 antibody inhibited the in vitro growth of B. microti parasites in RBCs by 80% at a 1:15 serum dilution (Fig. 6 ) strongly suggests that this molecule plays an important role in the invasion process and should be evaluated as a vaccine candidate against B. microti. Nonetheless, it is important that, similarly to Plasmodium parasite results (64) , multiple RBC receptor/parasite ligand pairs and associated mechanisms may be involved in mediating the B. microti invasion into RBCs. Indeed, the earlier reports suggested that B. rodhaini utilizes complement C3 as a bridge molecule for merozoite invasion into RBCs (65, 66) . In this regard, the recent publication of the genome sequence of B. microti can be leveraged in future studies to identify other molecules that might be involved in RBC invasion and that could be evaluated as vaccine candidates against this important pathogen.
